• Doxorubicin Hydrochloride: Research Context and Evidence

  2026-10-04

  Doxorubicin hydrochloride, also known as Adriamycin HCl, is widely studied in cancer biology, delivery science, and cardiotoxicity research. This overview separates established research uses from supplier claims, examines findings from a 2025 dual-loaded liposome methods study, and explains why analytical performance, cellular effects, animal outcomes, and clinical relevance should not be treated as interchangeable evidence.

• TRIM21–ERK1/2 Signaling in Pituitary Adenomas

  2026-10-03

  A 2025 Neuro-Oncology study identifies TRIM21 as a context-dependent regulator of ERK1/2 signaling, pituitary adenoma proliferation, and dopamine-agonist resistance. Its integrated genetic, proteomic, biochemical, and pharmacological evidence nominates TRIM21 and Quisinostat-associated pathway modulation as research leads, while leaving clinical translation and target specificity unresolved.

• Estrogen Receptor–Autophagy Axis in Perimenopause

  2026-10-02

  This study integrates NHANES cohort data, a perimenopausal mouse model, network pharmacology, and inhibitor-based validation to examine how declining estradiol relates to cardiometabolic disease and multi-organ fibrosis. Its central contribution is evidence that receptor-dependent autophagy, including mTOR-regulated signaling, links estrogen exposure with structural protection of the heart, aorta, and kidneys.

• Bafilomycin C1 in High-Content Cell Assays

  2026-10-01

  Bafilomycin C1 provides a mechanistic way to perturb V-ATPase-dependent lysosomal acidification while high-content imaging captures broader cellular phenotypes. This article translates that principle into autophagy, apoptosis research, and iPSC-cardiomyocyte screening workflows with practical controls and troubleshooting guidance.

• Enzyme-Induced Hypoxia and Urothelial Inflammation

  2026-10-01

  Hudson and colleagues show that hypoxia duration separates an early urothelial stress response from later caspase-1-associated inflammation. Their enzyme-induced hypoxia model links prolonged exposure to a ROS–TXNIP–NLRP3 mechanism and provides a useful framework for interpreting verapamil as a pathway perturbation rather than a selective inflammasome probe.

• Standardized Whole-Blood Stimulation and Immunometabolism

  2026-09-30

  Zhao and colleagues present a standardized whole-blood stimulation protocol for examining how metabolic interventions reshape cytokine responses to innate immune and microbial stimuli. Its main contribution is methodological: by preserving the human blood environment while controlling stimulation, metabolic modulation, controls, and cytokine measurement, the workflow supports reproducible cohort-level immunometabolism studies.

• Vernakalant for Rapid Atrial Fibrillation Conversion

  2026-09-30

  This phase 3 randomized trial evaluated vernakalant hydrochloride as a rapid pharmacological strategy for converting atrial fibrillation to sinus rhythm. Its main contribution was evidence that an atrium-focused, early-activating potassium and frequency-dependent sodium channel blocker could terminate recent-onset atrial fibrillation within minutes, although safety monitoring and patient selection remain important.

• Saracatinib (AZD0530) Experimental Workflow

  2026-09-29

  Build reproducible Src/Abl kinase experiments with Saracatinib (AZD0530), from concentration selection and migration assays to pathway-level validation. The workflow also explains how findings on Reelin–SFK signaling can guide careful, hypothesis-driven extensions into synaptic research without overstating cross-domain evidence.

• Trifluoperazine 2HCl: Assay Workflows

  2026-09-29

  Build reproducible dopamine D2 receptor, macrophage ROS/autophagy, and cancer-screening assays with Trifluoperazine 2HCl. This practical guide combines concentration design, fresh-stock handling, orthogonal controls, and lessons from a structurally distinct PDK4 inhibitor study.

• Instant Clot-Forming Antibacterial Dressings

  2026-09-28

  A 2024 study developed a bilayer wound dressing combining tranexamic acid, an NO donor, and propolis to address hemorrhage and bacterial contamination simultaneously. The formulation produced a dense fibrin network and strong activity against Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii, while also highlighting important limits in translating material-level findings to clinical trauma care.

• NF 449: Interpreting P2X1 Selectivity in Platelets

  2026-09-28

  NF 449 is a potent purinergic receptor antagonist used to investigate ATP-driven P2X1 signaling in platelets. This article explains why potency depends on assay context, how to interpret dose-dependent selectivity, and what the evidence can—and cannot—support in antithrombotic agent research.

• Sphingosine-1-phosphate Workflows for Apoptosis Research

  2026-09-27

  Use Sphingosine-1-phosphate (S1P) to probe receptor-linked survival and apoptosis with workflows that connect early signaling to later cell-death readouts. A recent intracerebral hemorrhage study highlights an S1PR3-associated TNF-α/caspase-3 pathway, while practical controls help distinguish receptor effects from lipid handling and vehicle artifacts.

• A More Efficient GRO-seq Protocol for Bread Wheat

  2026-09-26

  Chen and colleagues describe a bread wheat GRO-seq workflow that adds rRNA depletion between nuclear RNA isolation and nascent RNA immunoprecipitation. In their enhancer-transcription application, the modification increased the proportion of valid sequencing data by 20-fold, offering a practical way to reduce sequencing waste in a large, complex genome.

• Berberrubine Chloride: Mechanisms and Research Use

  2026-09-25

  Berberrubine chloride is a research alkaloid with reported activity across cancer, urate regulation, and inflammation models. This evidence-focused guide separates product-dossier benchmarks from the narrower peer-reviewed antifungal evidence and summarizes practical use limits.

• Puromycin Aminonucleoside: Renal Injury Workflows

  2026-09-25

  Build a controlled podocyte injury model with a compound used to study proteinuria and glomerular damage—not as an antibiotic selection reagent. This guide connects practical cell and animal workflows with concentration, pH, solubility, and interpretation safeguards.

546 records 2/37 page Previous Next 12345 下5页 Last page